Form 4: Coherus BioSciences Director Acquires Stock Options

Rita A. Karachun, a director of Coherus BioSciences, acquired stock options for 168,000 shares on June 4, 2024, at an exercise price of $1.78.

Summary

• Rita A. Karachun, a director at Coherus BioSciences, acquired stock options on June 4, 2024.
• The options are for 168,000 shares of Coherus BioSciences common stock.
• The exercise price of the stock options is $1.78 per share.
• The options vest over three years, with one-third vesting on June 4, 2025, and the remainder vesting monthly thereafter, contingent upon continued service.
• The expiration date for the options is June 4, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative performance, but rather aligns director interests with shareholders.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management and shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 1/3rd after one year and the remainder monthly is a typical vesting arrangement.
• The ten-year expiration date is also a common feature of stock option grants.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates